In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 167 for your search:
Cancer Type/Condition:  Brain tumor, adult: Glioblastoma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 22 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EF-19, NCT01756729
2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Pharmaceutical / Industry
Protocol IDs: 020221, NCT00045968
3.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: EF-14, NCT00916409
4.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX110-04, NCT01480479
5.

Phase: Phase III
Type: Treatment
Status: Active
Age: Over 18
Sponsor: Other
Protocol IDs: IRB#10BN132, NCT01502280
6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 2 to 32
Sponsor: Pharmaceutical / Industry
Protocol IDs: CNS 0201, NCT00179907
7.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 501007705, NCT00301418
8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 021-003, NCT00394628
9.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: Over 65
Sponsor: Other
Protocol IDs: 2006P-000464, NCT00456612
10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2006-0709, NCT00555399
11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 2000.00, NCI-2009-01593, R01CA114218, FHCRC-2000.00, 8357, FHCRC-IR-6259, NCT00669669
12.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000637854, NCCTG-N0877, N0877, NCT00869401
13.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 08-342, CLBH589BUS42T, NCT00859222
14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000660545, RTOG-0929, NCT01026493
15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 85
Sponsor: Other
Protocol IDs: 3542, RO1 FD003542-01, NCT01044966
16.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: CDR0000664302, RTOG-0913, NCT01062399
17.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CASE4309, NCI-2010-00309, NCT01086345
18.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: BRN0012, SU-04202010-5726, 17774, NCT01120639
19.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: COZ-SIU 10-002-1, NCT01128218
20.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Pharmaceutical / Industry
Protocol IDs: Tg 511-08-01, NCT01156584
21.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: Not specified
Sponsor: Other
Protocol IDs: 26901-COGLI, NCT01205334
22.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 11585, H9H-MC-JBAI, NCT01220271
23.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: VB-111-122, NCT01260506
24.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2010-0429, BTTC11-02, NCT01266031
25.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1001010839, NCT01269853
1     
New Search